Ascendis Pharma A/S (NASDAQ:ASND) Receives $262.69 Average Target Price from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus rating of “Buy” from the seventeen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $264.4375.

Several equities research analysts recently commented on ASND shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, November 26th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday. Wolfe Research began coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 price objective on the stock. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $220.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, November 18th.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently added to or reduced their stakes in the stock. Braun Stacey Associates Inc. acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $18,678,000. Calamos Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at $1,282,000. Allianz Asset Management GmbH boosted its stake in Ascendis Pharma A/S by 144.7% during the second quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock worth $1,605,000 after acquiring an additional 5,500 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Ascendis Pharma A/S in the second quarter worth $897,000. Finally, Kennedy Capital Management LLC grew its holdings in Ascendis Pharma A/S by 630.5% in the second quarter. Kennedy Capital Management LLC now owns 18,628 shares of the biotechnology company’s stock worth $3,215,000 after purchasing an additional 16,078 shares during the period.

Ascendis Pharma A/S Stock Up 0.5%

NASDAQ ASND opened at $216.66 on Monday. The company has a market cap of $13.43 billion, a price-to-earnings ratio of -48.80, a price-to-earnings-growth ratio of 1.14 and a beta of 0.46. Ascendis Pharma A/S has a twelve month low of $118.03 and a twelve month high of $229.94. The business’s fifty day moving average is $209.53 and its 200 day moving average is $198.79.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million during the quarter, compared to analysts’ expectations of $246.91 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.